We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Placental Tissue Found Similar to ESCs

By Biotechdaily staff writers
Posted on 09 Aug 2005
Although it is routinely discarded as medical waste, placental tissue may be an abundant source of cells with the same potential to treat diseases and regenerate tissues as embryonic stem cells (ESCs), according to a study published in the August 4, 2005, online edition of Stem Cells Express.

A part of the placenta called the amnion is comprised of cells that have strikingly similar characteristics of ESCs, reported the study's researchers, including the ability to express two key genes that give embryonic stem cells their unique capability for developing into any kind of specialized cell. More...
The study results suggest that these amniotic epithelial cells could in fact be directed to form liver, pancreas, heart, and nerve cells under the right conditions.

The amnion, derived from the embryo, forms as early as eight days after fertilization, when the fate of cells has yet to be determined, and serves to protect the developing fetus. The new studies using placentas from full-term pregnancies show that amniotic epithelial cells have many of the telltale surface markers of ESCs and also express the Oct-4 and nanog genes known to be required for self-renewal and pluripotency, which is the ability to develop into any kind of cell.

On the other hand, amniotic epithelial cells are not stem cells per se because they cannot grow indefinitely. This may be due to the fact that they do not express telomerase, important for DNA and chromosome replication and, by extension, cell division.

"Perhaps it's to their advantage that the amnion epithelial cells lack telomerase expression, because telomerase is associated with many cancers and one of the main concerns about stem cell therapies is that transplanted stem cells would replicate in the recipient to form tumors,” noted first author, Toshio Miki, M.D., Ph.D., an instructor in the department of pathology at the University of Pittsburgh School of Medicine (PA, USA).

To determine if amnion-derived cells delivered directly to tissues might cause tumors, the researchers conducted studies in immune system-deficient mice and found no evidence that tumors had developed seven months after the cells were injected into multiple sites. One advantage of amniotic epithelial cells is that they can double in population about 20 times over without needing another cell type to serve as a feeder cell layer. Instead, they create their own feeder layer, averting the need for using mice cells.

With the addition of various growth factors, the authors report the amnion-derived cells could differentiate to become liver cells, heart cells, the glial and neuronal cells that make up the nervous system, and pancreatic cells with genetic markers for insulin and glycogen production.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.